Let’s have a detailed review of the company and analytics of the Earum Pharmaceuticals IPO release date, IPO offer price, subscription, Earum Pharmaceuticals IPO allotment, grey market price and other details like the company’s background, its financial positions, its promoters and other related things.

Earum Pharmaceuticals is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products. Stock Broker Complaints

Earum Pharmaceuticals IPO Review & Ratings

IPO Ratings & Review
Industry Sentiments7.5/10
Industry Ranking7.1/10
Company Background7.4/10
Company Reputation7.2/10
Competitive Edge7.7/10
Financial Statements7.1/10
Popularity Index7.4/10
Promoters Reputation7.7/10
Retail Appetite7.1/10
Top Brokers Review7.5/10
Overall Ratings7.3/10
Star Ratings★★★☆☆

Summary of Earum Pharmaceuticals IPO

Earum Pharmaceuticals IPOEarum Pharmaceuticals Limited  is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products. 

As per Restated Financial statements

  • For the nine (9) months period ended December 31, 2018 and fiscal 2018, 2017 and 2016, their total revenues were Rs. 3450.35 lakhs, Rs. 3584.65 lakhs, Rs. 2369.27 lakhs, and Rs. 1863.00 lakhs, respectively.
  • The net asset value per Equity Share was Rs. 164.50 and Rs. 136.46 as of Dec 30, 2018 and March 31, 2018, respectively, as per the Restated Financial Statements 
  • The net worth of the company as on March 31, is  Rs. 421.08 lakhs as per the Restated Ind AS Consolidated Summary Statement of Assets and Liabilities.
  • The Profit after Tax for the similar period mentioned above was Rs. 86.51 lakhs, Rs. 85.65 lakhs, Rs. 15.98 lakhs, and Rs. 9.76 lakhs, respectively.

The Promoters of this company are Mr. Bhumishth Narendrabhai Patel, Mrs. Payal Bhumishth PatelThe lead manager to the issue is Hem Securities Limited and the Registrar to this issue is Bigshare Services Private Limited.

Open Free* Demat A/C Now! Fill the details below

    Fill Your Details Here

    Earum Pharmaceuticals IPO Date

    The opening and the closing date of Earum Pharmaceuticals IPO is Jun 21 – Jun 26, 2019.

    Earum Pharmaceuticals IPO Subscription

    Day / DateNIIRIITotal Subscription
    1st Day – Jun 211.16x0.02x0.59x
    2nd Day – Jun 241.29x0.25x0.77x
    3rd Day – Jun 251.30x0.32x0.81x
    4th Day – Jun 26
    Shares Offered or Net Issue876,000876,0001,752,000

    The shares subscribed by the public will be updated herein on a daily basis, once the IPO is open for subscription.

    Earum Pharmaceuticals IPO Allotment Status

    Here, you can find the Allotment Status of this IPO.

    Basis of Allotment FinalizationJul 1, 2019
    Refunds InitiationJul 2, 2019
    Credit of Shares to Demat AccountJul 3, 2019
    Share Listing DateJul 4, 2019

    Earum Pharmaceuticals IPO Price Band

    The face value of each share is Rs 10, but the price band of the IPO is Rs 36. 

    Earum Pharmaceuticals IPO Equity Share Offering

    This is an Initial Public Fresh Issue of 18,48,000 Equity Shares of face value of Rs. 10 each of the Company for cash at a price of Rs. 36 per Equity Share (including a share premium of Rs. 26 per Equity Share) aggregating up to Rs. 665 lakhs.

    Earum Pharmaceuticals Limited – Company Overview

    Earum Pharmaceuticals Limited was originally incorporated as “Earum Pharmaceuticals Private Limited” on July 26, 2012. On January 10, 2019, the company was converted into a Public Limited Company and consequently the name of the Company was changed from “Earum Pharmaceuticals Private Limited” to “Earum Pharmaceuticals Limited” vide a fresh Certificate of Incorporation dated January 23, 2019 provisions of the Companies Act, 1956.

    Earum Pharmaceuticals Product Line

    It is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic &anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections.

    They also offer around 125 pharmaceutical formulation products, of which around 24 products are marketed by us under their own brandname, the manufacturing of which is outsourced by them to third parties. Apart from pharmaceutical formulation products, they also deal in trading of active pharmaceutical ingredients (API’s) such as Levofloxacin Hemihdrate IP Albendazol IP, Amoxicillin Trihydrate IP etc.

    They have the registered office, corporate office and warehouse situated at Ahmedabad (Gujarat).

    Competitive Strengths of Earum Pharmaceuticals Limited:

    • Diversified Product Portfolio
    • Experienced Promoter and Management Team
    • Quality Assurance

    Business strategies of Earum Pharmaceuticals Limited:

    • Make their presence in Global Market
    • Leveraging their Marketing skills and Relationships
    • Focus on dealing in quality standard products
    • To build-up a professional organization
    • Develop cordial relationship with their Suppliers, Customer and employees

    Earum Pharmaceuticals Limited – Financial Statements

    A quick look into the past financial performance of the company to understand its performance of business and evaluate the growth prospectus:

    Financial Summary Earum Pharma IPO

    On the basis of Standalone statement:

    Amount (in INR & lakhs)
    Total Assets2,741.00 22,492.591,108.45 878.71
    Total Revenue3,450.35 3,584.65 2,369.27 1,863.00
    Total Expense3,330.69 3,460.51 2,345.60 1,846.96
    Profit After Tax86.51 85.6515.98  9.76

    Earnings per Equity Share (in lakhs)

    Basic & Diluted2.003.501.060.88

    From the above statements, one could find that the Earum Pharmaceuticals Limited may perform well.

    Earum Pharmaceuticals IPO – Promoters

    The Promoters of this company are:

    • Mr. Bhumishth Narendrabhai Patel
    • Mrs. Payal Bhumishth Patel

    List of Related Parties (Key Managerial Personnel)

    • Mr. Bhumishth Narendrabhai Patel – Managing Director
    • Mrs. Payal Bhumishth Patel – Whole Time Director
    • Ms. Ashna Sangwan – CFO
    • Mr. Mr. Parsotam Kantilal Purohit – Compliance officer & CS

    Interest in promotion of the Company

    Company is currently promoted by the Promoters in order to carry on its present business. Promoters are interested in the Company to the extent of their shareholding and directorship of the Individual Promoter in the Company and the dividend declared, if any, by the Company. The Promoters are interested in the transactions entered into the Company and the Promoter Group.

    Property Interest

    The promoters along with the promoter group will continue to hold collectively some percentage of the equity share capital of the company.

    As a result of the same, they will be able to exercise significant influence over the control of the outcome of the matter that requires approval of the majority shareholders vote.

    Interest in Intellectual Rights of the Company

    Promoters has not shown any interest in acquiring the intellectual rights of the company.

    Earum Pharmaceuticals IPO Offer Details or Earum Pharma IPO Issue Details

    Particulars No. Of Equity Shares
     Equity Shares Offered 18,48,000 Equity Shares aggregating up to Rs. [●] lakhs
     Of which:
     Reserved for Market Makers [●] Equity Shares aggregating up to Rs. [●] lakhs
     Net Issue to the Public [●] Equity Shares aggregating up to Rs. [●] lakhs
     Of which:
     Retail Investors Portion At least [●] Equity Shares aggregating up to Rs. [●] lakhs will be available for allocation to Retail Individual Investors
     Non-Retail Investors PortionNot more than [●] Equity Shares aggregating up to Rs. [●] lakhs will be available for allocation to investors other than Retail Individual Investors including Non- Institutional Investors and Qualified Institutional Buyers
     Equity Shares outstanding prior to the Issue43,19,910 Equity Shares
     Equity Shares outstanding after the IssueUpto 61,67,910 Equity Shares of face value of Rs. 10 each

    Earum Pharma IPO Issue Object

    These are the IPO Issue Objects of the company

    • Funding the Working Capital requirements of the Company:
    •  Repayment/ pre-payment of certain unsecured loans availed from banks and financial institutions by the company

    Earum Pharma IPO – Basis of the Offer Price

    The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.

    Qualitative factors are:

    • Diversified Product Portfolio
    • Experienced Promoter and Management Team
    • Quality Assurance

    The relevant quantitative factors are:

    Basic & Diluted EPSRONW in %NAV (Rs.)
    • Price to Earnings (P/E) ratio in relation to Issue Price of [●]
    ParticularsP/E ratio

    Competitive Peers Earum Pharmaceuticals IPO

    Sr. No. ParticularsFace Value  (in Rs.) EPS (In Rs.)P/E RatioRONW (%) NAV (In Rs.)
    1Earum Pharmaceuticals Limited103.50[●]20.34136.86
    2Vaishali Pharma Ltd.*101.430.963.8725.83

    Earum Pharmaceuticals IPO Lead Managers

    Lead Managers
    904,A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel,
    Mumbai-400013, India
    Tel. No.: +91- 022- 49060000 Fax No.: +91- 022- 22625991
    Website: www.hemsecurities.com
    Email: ib@hemsecurities.com
    Investor Grievance Email: redressal@hemsecurities.com
    Contact Person :Mr. Anil Bhargava
    SEBI Regn. No. INM000010981

    Earum Pharmaceuticals IPO Registrar to offer

    Registrar to the Offer
    Address -1st Floor, Bharat Tin Works Building,
    Opp. Vasant Oasis, Makwana Road,
    Marol, Andheri East, Mumbai – 400059
     – 400072. India. Tel. No. – 022 – 62638200
    Website: www.bigshareonline.com/ Email: ipo@bigshareonline.com
    Investor Grievance Email: investor@bigshareonline.com
    Contact Person: Mr. Ashok Shetty Regn. No. INR000001385

    Other Details of Earum Pharma IPO

    • Statutory Auditor –M/s. J M Patel & Bros.
    • Peer Review Auditor – M/s. J M Patel & Bros.
    • Bankers to the Company – State Bank of India

    Earum Pharma IPO Review by Top 10 Stock Brokers

    Top Stock Brokers ReviewCompany ReputationCompetitive EdgeFinancial StatementPopularity IndexPromoters Reputation
    Angel Broking7.2/107.4/107.2/107.1/107.1/10
    Kotak Securities7.3/107.2/107.4/107.1/107.2/10
    ICICI Direct7.4/107.3/107.7/107.2/107.1/10
    Motilal Oswal7.1/107.1/107.7/107.3/107.2/10

    Earum Pharmaceuticals IPO Grey Market Premium

    The Earum Pharmaceuticals IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X. 

    Open Free* Demat A/C Now! Fill the details below

      Fill Your Details Here

      Earum Pharmaceuticals IPO News

      News 1 – IPO ISSUE OPENS SOON [Download Prospectus]

      Market Guide

      Featured Topics

      Leave a Reply

      Your email address will not be published. Required fields are marked *

      24 + 9 =

      Get 90% Discount on Brokerage Now! Open Demat Account